| Literature DB >> 35469366 |
Yuriko Iwakura1,2, Ryoka Kawahara-Miki3, Satoshi Kida4,5, Hidekazu Sotoyama6, Ramil Gabdulkhaev7, Hitoshi Takahashi7, Yasuto Kunii8,9, Mizuki Hino8,9, Atsuko Nagaoka8, Ryuta Izumi8, Risa Shishido8, Toshiyuki Someya10, Hirooki Yabe8, Akiyoshi Kakita7, Hiroyuki Nawa6,11.
Abstract
The family of epidermal growth factor (EGF) including neuregulin-1 are implicated in the neuropathology of schizophrenia. We established a rat model of schizophrenia by exposing perinatal rats to EGF and reported that the auditory pathophysiological traits of this model such as prepulse inhibition, auditory steady-state response, and mismatch negativity are relevant to those of schizophrenia. We assessed the activation status of the auditory cortex in this model, as well as that in patients with schizophrenia, by monitoring the three neural activity-induced proteins: EGR1 (zif268), c-fos, and Arc. Among the activity markers, protein levels of EGR1 were significantly higher at the adult stage in EGF model rats than those in control rats. The group difference was observed despite an EGF model rat and a control rat being housed together, ruling out the contribution of rat vocalization effects. These changes in EGR1 levels were seen to be specific to the auditory cortex of this model. The increase in EGR1 levels were detectable at the juvenile stage and continued until old ages but displayed a peak immediately after puberty, whereas c-fos and Arc levels were nearly indistinguishable between groups at all ages with an exception of Arc decrease at the juvenile stage. A similar increase in EGR1 levels was observed in the postmortem superior temporal cortex of patients with schizophrenia. The commonality of the EGR1 increase indicates that the EGR1 elevation in the auditory cortex might be one of the molecular signatures of this animal model and schizophrenia associating with hallucination.Entities:
Keywords: Auditory cortex; Auditory hallucination; Early growth response 1; Epidermal growth factor; Immediate early gene; Schizophrenia
Mesh:
Substances:
Year: 2022 PMID: 35469366 DOI: 10.1007/s11064-022-03599-9
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 4.414